Here, we report a metastatic breast cancer case where a germline BRCA2 mutation was identified via tissue-based gene panel testing, necessitated by prior bone marrow transplantation precluding standard blood-based BRCA1/2 testing. This evidence concerns the gene BRCA2 and breast carcinoma.